vs
景顺（IVR）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是景顺的1.7倍（$35.5M vs $21.3M），景顺净利率更高（242.2% vs -304.2%，领先546.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 55.4%），过去两年景顺的营收复合增速更高（74.2% vs 60.5%）
景顺是一家美国独立投资管理公司，总部位于佐治亚州亚特兰大，在全球20个国家设有分支机构。景顺旗下拥有景顺、景顺 perpetual、PowerShares等多个品牌，其普通股纳入标普500指数，在纽约证券交易所挂牌交易。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
IVR vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.7倍
$21.3M
营收增速更快
RXRX
高出626.3%
55.4%
净利率更高
IVR
高出546.5%
-304.2%
两年增速更快
IVR
近两年复合增速
60.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $35.5M |
| 净利润 | $51.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 242.2% | -304.2% |
| 营收同比 | 55.4% | 681.7% |
| 净利润同比 | 1368.7% | 39.6% |
| 每股收益（稀释后） | $0.72 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVRRXRX
| Q4 25 | $21.3M | $35.5M | ||
| Q3 25 | $17.6M | $5.2M | ||
| Q2 25 | $17.7M | $19.2M | ||
| Q1 25 | $18.8M | $14.7M | ||
| Q4 24 | $13.7M | $4.5M | ||
| Q3 24 | $7.5M | $26.1M | ||
| Q2 24 | $8.6M | $14.4M | ||
| Q1 24 | $7.0M | $13.8M |
净利润IVRRXRX
| Q4 25 | $51.5M | $-108.1M | ||
| Q3 25 | $53.5M | $-162.3M | ||
| Q2 25 | $-23.3M | $-171.9M | ||
| Q1 25 | $19.6M | $-202.5M | ||
| Q4 24 | $3.5M | $-178.9M | ||
| Q3 24 | $40.7M | $-95.8M | ||
| Q2 24 | $-13.5M | $-97.5M | ||
| Q1 24 | $29.1M | $-91.4M |
毛利率IVRRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率IVRRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率IVRRXRX
| Q4 25 | 242.2% | -304.2% | ||
| Q3 25 | 303.6% | -3135.3% | ||
| Q2 25 | -131.6% | -894.2% | ||
| Q1 25 | 104.4% | -1373.3% | ||
| Q4 24 | 25.6% | -3935.5% | ||
| Q3 24 | 542.2% | -367.5% | ||
| Q2 24 | -155.9% | -676.6% | ||
| Q1 24 | 415.9% | -662.4% |
每股收益（稀释后）IVRRXRX
| Q4 25 | $0.72 | $-0.17 | ||
| Q3 25 | $0.74 | $-0.36 | ||
| Q2 25 | $-0.40 | $-0.41 | ||
| Q1 25 | $0.26 | $-0.50 | ||
| Q4 24 | $-0.09 | $-0.56 | ||
| Q3 24 | $0.63 | $-0.34 | ||
| Q2 24 | $-0.38 | $-0.40 | ||
| Q1 24 | $0.49 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $56.0M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $797.5M | $1.1B |
| 总资产 | $6.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资IVRRXRX
| Q4 25 | $56.0M | $743.3M | ||
| Q3 25 | $58.5M | $659.8M | ||
| Q2 25 | $59.4M | $525.1M | ||
| Q1 25 | $42.9M | $500.5M | ||
| Q4 24 | $73.4M | $594.4M | ||
| Q3 24 | $48.3M | $427.6M | ||
| Q2 24 | $58.8M | $474.3M | ||
| Q1 24 | $59.9M | $296.3M |
总债务IVRRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益IVRRXRX
| Q4 25 | $797.5M | $1.1B | ||
| Q3 25 | $769.6M | $1.0B | ||
| Q2 25 | $709.4M | $919.1M | ||
| Q1 25 | $759.2M | $933.9M | ||
| Q4 24 | $730.7M | $1.0B | ||
| Q3 24 | $857.0M | $524.6M | ||
| Q2 24 | $759.2M | $584.4M | ||
| Q1 24 | $785.6M | $401.2M |
总资产IVRRXRX
| Q4 25 | $6.5B | $1.5B | ||
| Q3 25 | $6.0B | $1.4B | ||
| Q2 25 | $5.4B | $1.3B | ||
| Q1 25 | $6.2B | $1.3B | ||
| Q4 24 | $5.7B | $1.4B | ||
| Q3 24 | $6.1B | $726.5M | ||
| Q2 24 | $5.1B | $775.9M | ||
| Q1 24 | $5.2B | $557.8M |
负债/权益比IVRRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $157.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 3.05× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流IVRRXRX
| Q4 25 | $157.1M | $-46.1M | ||
| Q3 25 | $37.3M | $-117.4M | ||
| Q2 25 | $40.6M | $-76.4M | ||
| Q1 25 | $19.3M | $-132.0M | ||
| Q4 24 | $183.2M | $-115.4M | ||
| Q3 24 | $30.8M | $-59.2M | ||
| Q2 24 | $33.0M | $-82.2M | ||
| Q1 24 | $57.5M | $-102.3M |
自由现金流IVRRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率IVRRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度IVRRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率IVRRXRX
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
